


IN THE CLAIMS:

1. (Currently amended) A method of enhancing paracellular permeability at an absorption site in a subject, the method comprising:
 - (a) administering an effective amount of a phospholipase C inhibitor to a subject at a time in which enhanced paracellular permeability is desired, wherein the phospholipase C inhibitor comprises the following structure:



- (i) where $n = \text{[[12]] } 13\text{-}19$; and
 - (b) enhancing paracellular permeability in the subject at the absorption site through the administering of the effective amount of the phospholipase C inhibitor.
2. (Canceled)
3. (Canceled)
4. (Withdrawn) The method of claim 2, wherein the 3-halocoumarin is 3-fluorocoumarin or derivative thereof, 3-chlorocoumarin or derivative thereof, or 3-iodocoumarin or derivative thereof.
5. (Withdrawn) The method of claim 2, wherein the N-alkylsuccinimido steroid derivative comprises an alkyl chain of one to ten methylene groups.

6. (Original) The method of claim 1, wherein the absorption site comprises intestinal epithelium.
 7. (Withdrawn) The method of claim 1, wherein the absorption site comprises the blood brain barrier.
 8. (Original) The method of claim 1, wherein the phospholipase C inhibitor is formulated for oral, buccal, rectal or transdermal administration, or in a form suitable to contact colonic epithelium, or in a form suitable for administration by inhalation or insufflation.
- 9-27. (Canceled)